Juvena Therapeutics leverages artificial intelligence and insights from human stem cell biology to engineer first-in-class regenerative biologics aimed at reversing tissue degeneration. Its lead candidate, JUV-161, is in Phase 1 studies and has shown preclinical benefits in myogenesis, muscle metabolism, and strength for myopathic conditions; dosing is complete in five of six SAD cohorts and all MAD cohorts with study completion expected by January. The company recently signed a research and collaboration agreement with Eli Lilly worth more than $650 million in potential milestones, underscoring the commercial interest in its platform. Proceeds from the latest financing will fund advancement of JUV-161, expansion of its pipeline targeting neuromuscular and age-related diseases, and further development of its AI discovery capabilities. Juvena is also pursuing additional partnership opportunities and has launched a search for a new CEO as it scales. Headquartered in Redwood City, California, the company has expanded its board and clinical leadership team to support its next phase of growth. No revenue or user metrics have been disclosed, but the company positions itself as a leader in regenerative medicine.

Total raised

$75M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2026